Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volasertib - Oncoheroes Biosciences/Notable Labs

Next Previous
Drug Profile

Volasertib - Oncoheroes Biosciences/Notable Labs

Alternative Names: BI-6727; NBL-001

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Oncoheroes Biosciences
  • Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Rhabdomyosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
  • No development reported Chronic myelomonocytic leukaemia; Rhabdomyosarcoma; Solid tumours; Urogenital cancer

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Ovarian cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Rhabdomyosarcoma in Unknown (IV, Infusion)
  • 24 Jul 2024 US FDA approves IND application for Volasertib in Acute myeloid leukemia (Second-line therapy or greater)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top